Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 16/20 | 0.54 |
| ▸ | F2 | P00734 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | F3 | P13726 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861159 | 1.00 | F7 (0.54) | F7F2KDM4EMAPTHTT | |
| SCHEMBL861192 | 0.90 | F7 (0.53) | F7F2F10PRSS1PRSS2 | |
| SCHEMBL842286 | 0.87 | F7 (0.52) | F7F2F10PRSS1PRSS2 | |
| SCHEMBL841234 | 0.87 | F7 (0.52) | F7F2F10PRSS1PRSS2 | |
| SCHEMBL860981 | 0.86 | F7 (0.51) | F7F2F10 | |
| SCHEMBL861200 | 0.84 | F7 (0.50) | F7F2F10 | |
| SCHEMBL860984 | 0.83 | F7 (0.49) | F7F2F10 | |
| SCHEMBL860383 | 0.83 | F7 (0.49) | F7F2F10 | |
| SCHEMBL8108603 | 0.83 | F7 (0.49) | F7F2F10 | |
| SCHEMBL860516 | 0.82 | F7 (0.48) | F7F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | F7, F9, TFPI | F7 1/4885F2 23/4885KDM4E 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.